raloxifene hydrochloride has been researched along with Prostatic Neoplasms in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Amodeo, P; Arroyo, FJ; Bianchini, G; De Petrocellis, L; López-Alvarado, P; Martín, MA; Menéndez, JC; Orlando, P; Roncero, C; Sánchez, A; Schiano Moriello, A; Vitale, RM | 1 |
| Tong, D | 1 |
| Aquino, AM; de Freitas, ATAG; Delella, FK; Gonçalves, BF; Justulin, LA; Mendes, LO; Pinho, CF; Salata, GC; Scarano, WR | 1 |
| Kapoor, S | 1 |
| Crippa, V; Messi, E; Piccolella, M; Poletti, A; Tetel, MJ | 1 |
| Casa, AJ; Cui, X; Dearth, RK; Lee, AV; Litzenburger, BC | 1 |
| Alexi, X; Alexis, MN; Fokialakis, N; Haroutounian, SA; Kasiotis, KM; Lambrinidis, G; Meligova, AK; Mikros, E | 1 |
| Abbondanza, C; Bellastella, A; Bellastella, G; Chieffi, P; De Bellis, A; De Rosa, C; Della Ragione, F; Maione, L; Prezioso, D; Rossi, V; Sinisi, AA; Visconti, D | 1 |
| Clarke, BL; Khosla, S | 1 |
| Hong, YJ; Kim, BC; Kim, HT; Kim, IY; Kim, SJ; Lee, DK; Morton, RA; Seo, JM; Seong, DH | 1 |
| Fallon, MA; Finkelstein, JS; Lee, H; Smith, MR | 1 |
| Chen, Y; Imaida, K; Kakehi, Y; Matsuda, Y; Saoo, K; Takeuchi, H; Yamakawa, K; Yokohira, M; Zeng, Y | 1 |
| Agus, DB; Bender, LI; Cinman, N; Galkin, AV; Green, L; Gross, M; Holden, S; Jain, A; Kaplan, L; Natale, RB; Nguyen, KN; Shazer, RL | 1 |
| Dunn, BK; Ford, LG | 1 |
| González Macías, J; Olmos Martínez, JM | 1 |
| Kong, CZ; Zhang, YX | 1 |
| Best, KL; Counts, DF; Goode, RL; Hoover, DM; Jones, CD; Merriman, RL; Neubauer, BL; Sarosdy, MF; Shaar, CJ; Tanzer, LR | 1 |
| Ziegler, J | 1 |
| Kim, BC; Kim, IY; Kim, SJ; Leach, F; Lee, DK; Morton, RA; Remaley, AT; Seong, DH | 1 |
| de Launoit, Y; Dufour, M; Labrie, F; Simard, J; Veilleux, R | 1 |
5 review(s) available for raloxifene hydrochloride and Prostatic Neoplasms
| Article | Year |
|---|---|
Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment.
Topics: Estradiol; Estrogen Receptor beta; Humans; Male; Prostatic Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Microenvironment | 2022 |
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Male; Neoplasms; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Signal Transduction; Treatment Outcome | 2008 |
Modulators of androgen and estrogen receptor activity.
Topics: Androgen Receptor Antagonists; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Male; Osteoporosis; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Finasteride; Humans; Male; Primary Prevention; Prostatic Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
[Osteoporosis in cancer survivors].
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fractures, Bone; Humans; Hypogonadism; Male; Middle Aged; Neoplasms; Osteoporosis; Prostatic Neoplasms; Radiotherapy; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2007 |
2 trial(s) available for raloxifene hydrochloride and Prostatic Neoplasms
| Article | Year |
|---|---|
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Testosterone | 2004 |
Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.
Topics: Aged; Aged, 80 and over; Animals; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2006 |
14 other study(ies) available for raloxifene hydrochloride and Prostatic Neoplasms
| Article | Year |
|---|---|
Tetrahydroisoquinoline-Derived Urea and 2,5-Diketopiperazine Derivatives as Selective Antagonists of the Transient Receptor Potential Melastatin 8 (TRPM8) Channel Receptor and Antiprostate Cancer Agents.
Topics: Animals; Antineoplastic Agents; Calcium; Cell Proliferation; Diketopiperazines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Prostatic Neoplasms; Structure-Activity Relationship; Tetrahydroisoquinolines; TRPM Cation Channels; Tumor Cells, Cultured; Urea | 2016 |
Raloxifene decreases cell viability and migratory potential in prostate cancer cells (LNCaP) with GPR30/GPER1 involvement.
Topics: Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Male; MAP Kinase Signaling System; Middle Aged; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction | 2019 |
Beyond breast carcinomas: the attenuating effect on tumor growth in other systemic malignancies by raloxifene.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Cell Line, Tumor; Colorectal Neoplasms; Female; Humans; Male; Prostatic Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Burden | 2013 |
Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Curcumin; Estradiol; Estrogen Receptor beta; Estrogen Receptor Modulators; Fulvestrant; Genistein; Humans; Male; Prostatic Neoplasms; Raloxifene Hydrochloride; Tamoxifen | 2014 |
Differential estrogen receptor subtype modulators: assessment of estrogen receptor subtype-binding selectivity and transcription-regulating properties of new cycloalkyl pyrazoles.
Topics: Adenocarcinoma; Binding Sites; Cell Line, Tumor; Estradiol; Humans; Male; Models, Molecular; Prostatic Neoplasms; Pyrazoles; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Transcription, Genetic | 2009 |
Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Dose-Response Relationship, Drug; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Gene Expression Regulation, Neoplastic; Humans; Male; Metallothionein; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Raloxifene Hydrochloride; Receptors, Thrombin; RNA, Messenger; Selective Estrogen Receptor Modulators; Signal Transduction; Time Factors; Transcription, Genetic | 2011 |
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Topics: Apoptosis; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured | 2002 |
Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
Topics: Adenocarcinoma; Androgen Antagonists; Androgen-Binding Protein; Animals; Animals, Genetically Modified; Antigens, Polyomavirus Transforming; Apoptosis; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Male; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Sulfonamides; Testosterone | 2005 |
Raloxifene can benefit prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Prostatic Neoplasms; Raloxifene Hydrochloride | 2006 |
[The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Topics: Apoptosis; Blotting, Western; Bone Density Conservation Agents; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Enzyme Inhibitors; Flavonoids; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; In Situ Nick-End Labeling; JNK Mitogen-Activated Protein Kinases; Male; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2008 |
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fluorouracil; Incidence; Lung Neoplasms; Lymphatic Metastasis; Male; Organ Size; Piperidines; Prostate; Prostatic Neoplasms; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Survival Rate; Testis; Weight Gain | 1995 |
Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drugs, Investigational; Estrogen Antagonists; Female; Humans; Lavandula; Male; Neoplasms; Oils, Volatile; Ovarian Neoplasms; Piperidines; Plant Oils; Plants, Medicinal; Prostatic Neoplasms; Raloxifene Hydrochloride; Retinoids; Tamoxifen; Toremifene | 1996 |
Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Topics: Androgens; Apoptosis; Dose-Response Relationship, Drug; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptors, Androgen; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured | 2002 |
Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.
Topics: Androgens; Androstane-3,17-diol; Binding, Competitive; Cell Cycle; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Antagonism; Estradiol; Estrogen Antagonists; Estrone; Flow Cytometry; Flutamide; Humans; In Vitro Techniques; Male; Metribolone; Piperidines; Prostatic Neoplasms; Raloxifene Hydrochloride; Tamoxifen; Testosterone; Time Factors; Tumor Cells, Cultured | 1991 |